Brought to you by 
Stemline Therapeutics completes $35.5mm IPO
06 Apr 2021
Executive Summary
Stemline Therapeutics Inc. (developing cancer stem cell-targeted treatments) has netted $35.5mm through its initial public offering. The company sold 3.8mm common shares (including the overallotment) at $10 each, just a few weeks after filing an amended S-1 stating that it hoped to sell 2,275,000 shares at a range of $10-12.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Stemline Therapeutics completes $35.5mm IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice